View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 24, 2017updated 27 Oct 2017 12:13pm

FDA grants orphan designation to TiGenix’s Cx601 for Crohn’s disease

The US Food and Drug Administration (FDA) has granted orphan drug designation to Belgian biopharmaceutical firm TiGenix’s Cx601 to treat patients with fistulizing Crohn’s disease.

The US Food and Drug Administration (FDA) has granted orphan drug designation to Belgian biopharmaceutical firm TiGenix’s Cx601 to treat patients with fistulizing Crohn’s disease.

Crohn’s disease is a chronic inflammatory condition characterised by the intestine and complex perianal fistulas.

Formulated for local administration, Cx601 comprises allogeneic (or donor-derived) expanded adipose-derived stem cells (eASCs) for treating complex perianal fistulas in patients who failed standard therapy.

TiGenix Regulatory Affairs and Corporate Quality vice-president Dr María Pascual said: “The granting of orphan drug status by the FDA is a significant step forward in the Cx601 development programme.

“The FDA’s recognition of Cx601 as an orphan drug brings a number of potential financial benefits and is aligned with our ongoing work seeking expedited pathways towards product approval in the US.”

“The granting of orphan drug status by the FDA is a significant step forward in the Cx601 development programme.”

Earlier this year, TiGenix commenced Cx601’s Phase III clinical trial to support a future submission of a US biologics licence application (BLA) to the FDA.

With orphan designation granted by European Commission in 2009, Cx601 is reported to have demonstrated favourable safety and efficacy profile in a Phase III trial completed in August 2015.

A follow-up analysis of the trial further confirmed the sustained safety and efficacy of Cx601.

TiGenix has already submitted a marketing authorisation application to the European Medicines Agency (EMA) and expects a CHMP opinion by the end of this year.

Under a licensing agreement formed with the firm in July last year, Takeda obtained exclusive development and commercialisation rights of Cx601 for complex perianal fistulas outside the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology